Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
13. A new advanced device for delivery of micro mechanical devices into the body.
14. A new advanced device for biopsy.
15. A new advanced device for stem cell treatment delivery.
16. A new advanced contact lens device.
Several more devices beyond this list will be revealed in coming months by the Company. This represents the beginning for EPGL technological development.
About EP Global Communications, Inc. / EPGL Medical
EP Global Communications, Inc. is a medical device manufacturer and marketing company with exclusive rights to a new FDA 510k cleared medical device called the Muscle Pain Detection Device. The MPDD is a revolutionary new diagnostic tool for the detection of muscular originated pain in the human body.
EPGL Medical Unveils New Devices and Intellectual Property Under EP Global Communications, Inc. Ownership
IRVINE, Jun 18, 2013 (GLOBE NEWSWIRE via COMTEX) - via PRWEB - EP Global Communications, Inc. (the Company), (Stock Ticker: EPGL) EPGL Medical Sciences, is pleased to announce several new devices resulting from the TopSpin technology recently announced. Many of these devices have not been revealed before today. To Compliment the MPDD, the new MPTT will be first to become a prototype this fall and new FDA 510k and PMA Applications are being prepared for filing during 3rd and 4th Quarters. EPGL has filed patents and owns unique Intellectual Property for each of the following new smart medical devices:
1. A new advanced ablation device for nerve pain treatment in the back.
2. A new advanced ablation device for nerve treatment of Facial Glabballar Frowning.
3. A new advanced device for elimination of facial wrinkles.
4. A new advanced Epidural device.
5. A new advanced power source for TopSpin medical devices.
6. A new and promising device for treatment of Retinitis Pigmentosa
7. A new and promising device for treatment of Macular Degeneration
8. A new and promising treatment for Hearing Loss
9. A new more accurate treatment for trigger points in the muscles (MPTT)
10. A new advanced device for treatment of prostate tumors.
11. A new advanced endoscopic device.
12. A new advanced device for delivery of micron sized drug payloads.
About Woulfe Mining Corp. "Unearthing Global Assets"
Woulfe Mining Corp. is focused on 'Unearthing Global Assets' through the recognition and development of undervalued natural resource projects. Woulfe differentiates itself by boasting significant technical expertise in the design, development and operation of mining projects.
Our flagship project is the Sangdong tungsten mine in South Korea, historically the world's largest tungsten mine for over 40 years. Sangdong is expected to return to production by Q4 of 2013. Woulfe has entered into strategic agreements with International Metalworking Companies B.V. ('IMC'), part of the Berkshire Hathaway group of companies. This partnership brings strategic advantage given Woulfe's mining and processing technical abilities and IMC's downstream manufacturing skills, high level of innovation and quality of products sold into the global tungsten market. Woulfe Mining Corp. is a Canadian TSX-V listed company. Further information can be found on Woulfe's website www.woulfemining.com or on info@woulfe.com.au.
Warren Buffet has it all now: Our flagship project is the Sangdong tungsten mine in South Korea, historically the world's largest tungsten mine for over 40 years. Sangdong is expected to return to production by Q4 of 2013. Woulfe has entered into strategic agreements with International Metalworking Companies B.V. ('IMC'), part of the Berkshire Hathaway group of companies. This partnership brings strategic advantage given Woulfe's mining and processing technical abilities and IMC's downstream manufacturing skills, high level of innovation and quality of products sold into the global tungsten market. Woulfe Mining Corp. is a Canadian TSX-V listed company. Further information can be found on Woulfe's website www.woulfemining.com or on info@woulfe.com.au.
Whole report of CBAI:Cord Blood America Announces 2013 First Quarter Financial Results
LAS VEGAS, May 15, 2013 /PRNewswire/ -- Cord Blood America, Inc. (www.cordblood-america.com) (OTC Bulletin Board: CBAI) ("CBAI" or the "Company") today announced financial results for the quarter ended March 31, 2013.
First Quarter 2013 Highlights From Continuing Operations
Recurring revenues increased approximately 7% for the three months ended March 31, 2013 to $740,124.
Cash provided by operations totaled $128,970 in the first quarter. This represents 68% of the total full year cash generated in 2012 of $190,323.
EBITDA for the quarter increased 587% to $99,985 from $14,542 in the year ago period.
SG&A decreased 11% to $1.11 million from $1.24 million in the year ago period.
Our cash balance increased 40% to $369,186 compared to the same period a year ago.
Joseph Vicente, President of Cord Blood America, Inc. commented "During the quarter, Biocordcell Argentina (Bio), made investments in lab related processes, causing increased costs which we expect to be primarily one-time charges. The Company believes these investments will help support future growth. We remain focused on reducing our corporate costs, which were down 11%, despite the increased costs from Bio in the first quarter. We also remain committed to ensuring that incremental revenue growth meets a corresponding increase in profitability, as the Company will not add to its debt under the current conditions. We remain bullish on the industry and our prospects for future growth."
I agree with you 100 percent PeteRose. After being in the conference call on Monday 24th, products and revenue is increasing:
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2013, FQ4/13 Revenues Highest in Corp
Elite Pharmaceuticals, Inc. (OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral abuse-resistant controlled release product formulations and the manufacturing of generic pharmaceuticals, announced results for the fiscal year ended March 31, 2013.
Consolidated revenues were $3.4 million for the fiscal year, an increase of $1.0 million or approximately 40% over consolidated revenues for the prior year. Revenues for the quarter ended March 31, 2013, were exceptionally strong, totaling $1.5 million, the highest quarterly revenue level in corporate history, 131% above quarterly revenues for the comparable period of the prior year. The large increases in revenues are the result of the successful launch and strong growth in new product revenues which have mostly been created during the past 18 months.
Since the end of the fiscal year, Elite launched two new products, Phentermine 15mg capsules and Phentermine 30mg capsules, both being distributed under license by TAGI Pharma. These new products did not generate revenues during the fiscal year ended March 31, 2013, but are generating revenues currently. Shortly, Elite will begin manufacture of naltrexone 50 mg tablets, a recently approved ANDA whose revenues are not represented in Elite's fiscal year 2013 results.
Elite's operations incurred a $1.9 million negative cash flow, due in large part to the financing of a $1.4 million increase inventory and receivables generated by the rapid increase in revenues.
Consolidated loss from operations was $1.6 million, and GAAP net income, including non-cash income relating to the accounting treatment of preferred share and warrant derivatives was $1.5 million. Basic earnings per share were $0.00 on a weighted average 349.1 million common shares outstanding. Fully diluted loss per share was $(0.00), on a weighted average of 526.9 million shares outstanding on a fully diluted basis.
Jerry Treppel, Chairman and CEO of Elite commented, "It has been a remarkable year for Elite. We launched new products, substantially increased our revenues, and lowered our operating losses. Most importantly, I can now tell you that we expect our first commercially scaled-up, abuse-resistant opioid product to enter human pilot studies later this year. We have also conducted work on another abuse-resistant opioid product. We have also received FDA feedback on clinical protocols for the extended release brompheniramine product and have filed a Citizen Petition regarding the extended release brompheniramine/pseudoephedrine product, which, if successful, would put this product in a position to also begin clinical trials and eventually secure approvals for bringing these products on to the market. The Company will host a conference call to discuss the results of operations and provide an update on recent business developments on Monday, June 24, 2013 at 11:00 AM EDT. Company executives will also conduct a question and answer session following their remarks.
To access the conference call:
Domestic callers: (800) 346-7359
International callers: (973) 528-0008
Conference Entry Code: 98840
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2013, FQ4/13 Revenues Highest in Corp
Elite Pharmaceuticals, Inc. (OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral abuse-resistant controlled release product formulations and the manufacturing of generic pharmaceuticals, announced results for the fiscal year ended March 31, 2013.
Consolidated revenues were $3.4 million for the fiscal year, an increase of $1.0 million or approximately 40% over consolidated revenues for the prior year. Revenues for the quarter ended March 31, 2013, were exceptionally strong, totaling $1.5 million, the highest quarterly revenue level in corporate history, 131% above quarterly revenues for the comparable period of the prior year. The large increases in revenues are the result of the successful launch and strong growth in new product revenues which have mostly been created during the past 18 months.
Since the end of the fiscal year, Elite launched two new products, Phentermine 15mg capsules and Phentermine 30mg capsules, both being distributed under license by TAGI Pharma. These new products did not generate revenues during the fiscal year ended March 31, 2013, but are generating revenues currently. Shortly, Elite will begin manufacture of naltrexone 50 mg tablets, a recently approved ANDA whose revenues are not represented in Elite's fiscal year 2013 results.
Elite's operations incurred a $1.9 million negative cash flow, due in large part to the financing of a $1.4 million increase inventory and receivables generated by the rapid increase in revenues.
Consolidated loss from operations was $1.6 million, and GAAP net income, including non-cash income relating to the accounting treatment of preferred share and warrant derivatives was $1.5 million. Basic earnings per share were $0.00 on a weighted average 349.1 million common shares outstanding. Fully diluted loss per share was $(0.00), on a weighted average of 526.9 million shares outstanding on a fully diluted basis.
Jerry Treppel, Chairman and CEO of Elite commented, "It has been a remarkable year for Elite. We launched new products, substantially increased our revenues, and lowered our operating losses. Most importantly, I can now tell you that we expect our first commercially scaled-up, abuse-resistant opioid product to enter human pilot studies later this year. We have also conducted work on another abuse-resistant opioid product. We have also received FDA feedback on clinical protocols for the extended release brompheniramine product and have filed a Citizen Petition regarding the extended release brompheniramine/pseudoephedrine product, which, if successful, would put this product in a position to also begin clinical trials and eventually secure approvals for bringing these products on to the market. The Company will host a conference call to discuss the results of operations and provide an update on recent business developments on Monday, June 24, 2013 at 11:00 AM EDT. Company executives will also conduct a question and answer session following their remarks.
To access the conference call:
Domestic callers: (800) 346-7359
International callers: (973) 528-0008
Conference Entry Code: 98840
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2013, FQ4/13 Revenues Highest in Corp
Elite Pharmaceuticals, Inc. (OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral abuse-resistant controlled release product formulations and the manufacturing of generic pharmaceuticals, announced results for the fiscal year ended March 31, 2013.
Consolidated revenues were $3.4 million for the fiscal year, an increase of $1.0 million or approximately 40% over consolidated revenues for the prior year. Revenues for the quarter ended March 31, 2013, were exceptionally strong, totaling $1.5 million, the highest quarterly revenue level in corporate history, 131% above quarterly revenues for the comparable period of the prior year. The large increases in revenues are the result of the successful launch and strong growth in new product revenues which have mostly been created during the past 18 months.
Since the end of the fiscal year, Elite launched two new products, Phentermine 15mg capsules and Phentermine 30mg capsules, both being distributed under license by TAGI Pharma. These new products did not generate revenues during the fiscal year ended March 31, 2013, but are generating revenues currently. Shortly, Elite will begin manufacture of naltrexone 50 mg tablets, a recently approved ANDA whose revenues are not represented in Elite's fiscal year 2013 results.
Elite's operations incurred a $1.9 million negative cash flow, due in large part to the financing of a $1.4 million increase inventory and receivables generated by the rapid increase in revenues.
Consolidated loss from operations was $1.6 million, and GAAP net income, including non-cash income relating to the accounting treatment of preferred share and warrant derivatives was $1.5 million. Basic earnings per share were $0.00 on a weighted average 349.1 million common shares outstanding. Fully diluted loss per share was $(0.00), on a weighted average of 526.9 million shares outstanding on a fully diluted basis.
Jerry Treppel, Chairman and CEO of Elite commented, "It has been a remarkable year for Elite. We launched new products, substantially increased our revenues, and lowered our operating losses. Most importantly, I can now tell you that we expect our first commercially scaled-up, abuse-resistant opioid product to enter human pilot studies later this year. We have also conducted work on another abuse-resistant opioid product. We have also received FDA feedback on clinical protocols for the extended release brompheniramine product and have filed a Citizen Petition regarding the extended release brompheniramine/pseudoephedrine product, which, if successful, would put this product in a position to also begin clinical trials and eventually secure approvals for bringing these products on to the market. The Company will host a conference call to discuss the results of operations and provide an update on recent business developments on Monday, June 24, 2013 at 11:00 AM EDT. Company executives will also conduct a question and answer session following their remarks.
To access the conference call:
Domestic callers: (800) 346-7359
International callers: (973) 528-0008
Conference Entry Code: 98840
Whole report of CBAI:Cord Blood America Announces 2013 First Quarter Financial Results
LAS VEGAS, May 15, 2013 /PRNewswire/ -- Cord Blood America, Inc. (www.cordblood-america.com) (OTC Bulletin Board: CBAI) ("CBAI" or the "Company") today announced financial results for the quarter ended March 31, 2013.
First Quarter 2013 Highlights From Continuing Operations
Recurring revenues increased approximately 7% for the three months ended March 31, 2013 to $740,124.
Cash provided by operations totaled $128,970 in the first quarter. This represents 68% of the total full year cash generated in 2012 of $190,323.
EBITDA for the quarter increased 587% to $99,985 from $14,542 in the year ago period.
SG&A decreased 11% to $1.11 million from $1.24 million in the year ago period.
Our cash balance increased 40% to $369,186 compared to the same period a year ago.
Joseph Vicente, President of Cord Blood America, Inc. commented "During the quarter, Biocordcell Argentina (Bio), made investments in lab related processes, causing increased costs which we expect to be primarily one-time charges. The Company believes these investments will help support future growth. We remain focused on reducing our corporate costs, which were down 11%, despite the increased costs from Bio in the first quarter. We also remain committed to ensuring that incremental revenue growth meets a corresponding increase in profitability, as the Company will not add to its debt under the current conditions. We remain bullish on the industry and our prospects for future growth."
For the three months ended March 31, 2013, total revenue increased to approximately $1.45 million from $1.43 million compared to the year ago period. Recurring revenues increased approximately 7% while tissue related sales increased at 31%, offset by an 11% decrease in processing fees.
Administrative and selling expenses for the three months ended March 31, 2013 were $1.11 million as compared to $1.24 million for the comparative period of 2012, representing an 11% decrease. These expenses are primarily related to marketing/advertising, professional services, allocated facility related expenses and wages for personnel. Generally, each functional unit within administrative and selling expenses has reduced expenses from the prior comparative period. The Company continues to evaluate its expenses and their relationship to revenues for alignment.
For the period ending March 31, 2013, the company had $0.39 million in cash, an increase of 40% from the prior comparative period total of $0.28 million. The Company currently collects cash receipts from operations through CBAI and its subsidiary, Bio-cells. Cash flows from operations are currently sufficient to fund operations. During the three month period ended March 31, 2013 there was no increase in notes payable for purposes of working capital or investment in affiliate companies. Net cash provided by operating activities for the three month period ending March 31, 2013 was $0.13 million, versus a use of $1.00 million cash from the prior comparative period of 2012, an improvement of $0.23 million.
Mr. Vicente concluded, "We have now completed four consecutive quarters operating off cash generated from our operations without any additional outside investment. To add additional clarity on the improvements we have made within the Company, in the first quarter of the prior year we took $458,664 in outside investment capital to fund operations compared to our current quarter, in which we did not take any investment capital, and instead generated $128,970 from operating activities."
About Cord Blood America
Cord Blood America, Inc. is the parent company of CorCell, Companies, Inc. which, along with Cord Blood America, Inc., facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. and CorCell Companies, Inc., visit our websites: http://www.cordblood-america.com/ for investor information and http://www.corcell.com/ for customer information.
Cord Blood America Announces 2013 First Quarter Financial Results
LAS VEGAS, May 15, 2013 /PRNewswire/ -- Cord Blood America, Inc. (www.cordblood-america.com) (OTC Bulletin Board: CBAI) ("CBAI" or the "Company") today announced financial results for the quarter ended March 31, 2013.
First Quarter 2013 Highlights From Continuing Operations
Recurring revenues increased approximately 7% for the three months ended March 31, 2013 to $740,124.
Cash provided by operations totaled $128,970 in the first quarter. This represents 68% of the total full year cash generated in 2012 of $190,323.
EBITDA for the quarter increased 587% to $99,985 from $14,542 in the year ago period.
SG&A decreased 11% to $1.11 million from $1.24 million in the year ago period.
Our cash balance increased 40% to $369,186 compared to the same period a year ago.
Joseph Vicente, President of Cord Blood America, Inc. commented "During the quarter, Biocordcell Argentina (Bio), made investments in lab related processes, causing increased costs which we expect to be primarily one-time charges. The Company believes these investments will help support future growth. We remain focused on reducing our corporate costs, which were down 11%, despite the increased costs from Bio in the first quarter. We also remain committed to ensuring that incremental revenue growth meets a corresponding increase in profitability, as the Company will not add to its debt under the current conditions. We remain bullish on the industry and our prospects for future growth."
Early buys
Cord Blood America Announces 2013 First Quarter Financial Results
LAS VEGAS, May 15, 2013 /PRNewswire/ -- Cord Blood America, Inc. (www.cordblood-america.com) (OTC Bulletin Board: CBAI) ("CBAI" or the "Company") today announced financial results for the quarter ended March 31, 2013.
First Quarter 2013 Highlights From Continuing Operations
Recurring revenues increased approximately 7% for the three months ended March 31, 2013 to $740,124.
Cash provided by operations totaled $128,970 in the first quarter. This represents 68% of the total full year cash generated in 2012 of $190,323.
EBITDA for the quarter increased 587% to $99,985 from $14,542 in the year ago period.
SG&A decreased 11% to $1.11 million from $1.24 million in the year ago period.
Our cash balance increased 40% to $369,186 compared to the same period a year ago.
Joseph Vicente, President of Cord Blood America, Inc. commented "During the quarter, Biocordcell Argentina (Bio), made investments in lab related processes, causing increased costs which we expect to be primarily one-time charges. The Company believes these investments will help support future growth. We remain focused on reducing our corporate costs, which were down 11%, despite the increased costs from Bio in the first quarter. We also remain committed to ensuring that incremental revenue growth meets a corresponding increase in profitability, as the Company will not add to its debt under the current conditions. We remain bullish on the industry and our prospects for future growth."
CVV is going to new highs. $$$$$
Cord Blood America Announces 2013 First Quarter Financial Results
LAS VEGAS, May 15, 2013 /PRNewswire/ -- Cord Blood America, Inc. (www.cordblood-america.com) (OTC Bulletin Board: CBAI) ("CBAI" or the "Company") today announced financial results for the quarter ended March 31, 2013.
First Quarter 2013 Highlights From Continuing Operations
Recurring revenues increased approximately 7% for the three months ended March 31, 2013 to $740,124.
Cash provided by operations totaled $128,970 in the first quarter. This represents 68% of the total full year cash generated in 2012 of $190,323.
EBITDA for the quarter increased 587% to $99,985 from $14,542 in the year ago period.
SG&A decreased 11% to $1.11 million from $1.24 million in the year ago period.
Our cash balance increased 40% to $369,186 compared to the same period a year ago.
Joseph Vicente, President of Cord Blood America, Inc. commented "During the quarter, Biocordcell Argentina (Bio), made investments in lab related processes, causing increased costs which we expect to be primarily one-time charges. The Company believes these investments will help support future growth. We remain focused on reducing our corporate costs, which were down 11%, despite the increased costs from Bio in the first quarter. We also remain committed to ensuring that incremental revenue growth meets a corresponding increase in profitability, as the Company will not add to its debt under the current conditions. We remain bullish on the industry and our prospects for future growth."
For the three months ended March 31, 2013, total revenue increased to approximately $1.45 million from $1.43 million compared to the year ago period. Recurring revenues increased approximately 7% while tissue related sales increased at 31%, offset by an 11% decrease in processing fees.
Administrative and selling expenses for the three months ended March 31, 2013 were $1.11 million as compared to $1.24 million for the comparative period of 2012, representing an 11% decrease. These expenses are primarily related to marketing/advertising, professional services, allocated facility related expenses and wages for personnel. Generally, each functional unit within administrative and selling expenses has reduced expenses from the prior comparative period. The Company continues to evaluate its expenses and their relationship to revenues for alignment.
For the period ending March 31, 2013, the company had $0.39 million in cash, an increase of 40% from the prior comparative period total of $0.28 million. The Company currently collects cash receipts from operations through CBAI and its subsidiary, Bio-cells. Cash flows from operations are currently sufficient to fund operations. During the three month period ended March 31, 2013 there was no increase in notes payable for purposes of working capital or investment in affiliate companies. Net cash provided by operating activities for the three month period ending March 31, 2013 was $0.13 million, versus a use of $1.00 million cash from the prior comparative period of 2012, an improvement of $0.23 million.
Mr. Vicente concluded, "We have now completed four consecutive quarters operating off cash generated from our operations without any additional outside investment. To add additional clarity on the improvements we have made within the Company, in the first quarter of the prior year we took $458,664 in outside investment capital to fund operations compared to our current quarter, in which we did not take any investment capital, and instead generated $128,970 from operating activities."
About Cord Blood America
Cord Blood America, Inc. is the parent company of CorCell, Companies, Inc. which, along with Cord Blood America, Inc., facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. and CorCell Companies, Inc., visit our websites: http://www.cordblood-america.com/ for investor information and http://www.corcell.com/ for customer information.
Have an excellent weekend Frogger.
Getting ready to fly out of Denver airport. Have a excellent weekend Frogger.
Thank you
Excellent to see you here Frogger. Bought a block. Thank you for last years profits. I owe you.
BCXQL has been my favorite play for the past year.
Axiologix, Inc. To Report Fiscal 4th Quarter Revenues Over $250,000; Up 33% From Same Period Last Year
SARASOTA, Fla., June 6, 2013 /PRNewswire/ -- Axiologix, Inc. (www.axiologix.net) (OTC Pink: AXLX), an International Technology and Services Organization focused on delivering Cloud-based Products and Services, today guides that revenues for the 4th fiscal quarter ending May 31, 2013 will be in excess of $250,000, an increase of 33% over the same period last year and up 4% on the previous quarter.
A comprehensive annual report will be filed with the OTC Markets Information Service on or before 90 days from May 31, 2013 in line with its reporting guidelines. The Company will announce interim results prior to this as relevant information becomes available. The Company intends to have the full year results audited as soon as possible on a path to relisting on the OTCQB at the earliest opportunity as a requirement of the funding process for pending acquisitions.
Cord Blood America Announces 2013 First Quarter Financial Results
LAS VEGAS, May 15, 2013 /PRNewswire/ -- Cord Blood America, Inc. (www.cordblood-america.com) (OTC Bulletin Board: CBAI) ("CBAI" or the "Company") today announced financial results for the quarter ended March 31, 2013.
First Quarter 2013 Highlights From Continuing Operations
Recurring revenues increased approximately 7% for the three months ended March 31, 2013 to $740,124.
Cash provided by operations totaled $128,970 in the first quarter. This represents 68% of the total full year cash generated in 2012 of $190,323.
EBITDA for the quarter increased 587% to $99,985 from $14,542 in the year ago period.
SG&A decreased 11% to $1.11 million from $1.24 million in the year ago period.
Our cash balance increased 40% to $369,186 compared to the same period a year ago.
Micro Imaging Technology to Exhibit the MIT 1000 at the 2013 Food Safety Summit
Micro Imaging Technology, Inc. (OTCQB: MMTC) announced that it will attend this year's Food Safety Summit Conference and exhibit the MIT 1000 in Baltimore, Maryland -- April 30 through May 2, 2013. Now in its 15th year, the Food Safety Summit provides important food safety information and solutions to those responsible for assuring food safety across the food supply chain.
The Food Safety Summit is a solutions-based conference and expo designed to meet the educational and information needs of the entire food industry including growers, processors, retailers, distributors, foodservice operators, regulators and academia. "We will continue to showcase the MIT 1000 to the Food Safety Industry through these events," stated Jeff Nunez, MIT's Chairman and CEO. "Our primary objective, dedication, and commitment, however, is to the development of additional 'Identifiers.' In the meantime, it is important that we continue to expose the Food Safety Industry and begin showing the Clinical Industry the speed, ease of use, accuracy, and low cost of the MIT 1000 System, which can be commercially used today for the pathogenic testing of Listeria species." Please visit us at Booth #610.
The MIT 1000 is a stand-alone, rapid laser based bacteria detection and identification technology; a software driven system that can detect pathogenic bacteria and complete an identifying test in under three (3) minutes (average) at significant cost savings per test. In June 2009, the AOAC Research Institute (AOAC RI) awarded the Company Performance Tested Methods SM (PTM) certification for the rapid identification of Listeria. The AOAC RI provides an independent third party evaluation and expert reviews of methods and will award PTM certification to methods that demonstrate performance levels equivalent or better than other certified bacteria identifying methods. The MIT System underwent hundreds of individual tests, including ruggedness and accuracy, to earn AOAC RI's certification for the identification of Listeria.
About: Micro Imaging Technology, Inc.
Micro Imaging Technology, Inc. is a California-based public company that is also registered to do business under the name Micro Identification Technologies. MIT has developed and patented the MIT-1000, a stand-alone, optically-based, software driven system that can detect pathogenic bacteria and complete an identification test, after culturing, in less than three (3) minutes (average) at the lowest cost per test when compared to any other conventional method. It does not rely on chemical or biological agents, conventional processing, fluorescent tags, gas chromatography or DNA analysis. The process requires only clean particle-free water and a sample of the unknown bacteria. Revenues for all rapid testing methods exceed $5 billion annually -- with food safety accounting for over $3.5 billion, which is expected to surpass $4.7 billion by 2015 according to BCC Research. In addition, the recently passed "New" U.S. Food Safety Bill is expected to further accelerate the current annual growth rate of 6.6 percent.
Micro Identification Technologies™. at www.micro-identification.com.
Elite Laboratories Files Citizen Petition With the FDA on Brompheniramine Maleate and Pseudoephedrine HCL Extended Release
Elite Laboratories, a wholly owned subsidiary of Elite Pharmaceuticals, Inc. (collectively ""Elite" or the "Company") (OTCBB:ELTP) today announced that the Company submitted a Citizen Petition to the U.S. Food and Drug Administration (the "FDA") requesting that the FDA make a determination that (a) it is suitable to use the currently approved and marketed ANDA product (ANDA 078648, generic to Drixoral brand) as the Reference Listed Drug ("RLD") since the current RLD Drixoral brand is no longer available in the marketplace, and (b) that this currently approved and marketed ANDA product is suitable to use as a RLD for an equivalent active ingredient comprised of a difference salt.
The filing of the Citizen Petition represents another step forward in Elite's continuing efforts to reintroduce its extended release brompheniramine maleate and pseudoephedrine hydrochloride to the marketplace.
Citizen petitions are filed to ask that the FDA take, or refrain from taking, a particular action. Any person may file a citizen petition, and any person may comment on a petition that has been filed. Petitions are governed by and must comply with FDA regulations, specifically 21 C.F.R. § 10.30, as well as the Federal Food, Drug, and Cosmetic Act, specifically 21 U.S.C. § 355(q) when applicable.
Elite cannot predict when or if the FDA will respond to, or otherwise take any action with respect to, the Citizen Petition.
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. develops oral sustained and controlled release products. Elite's strategy includes assisting partner companies in the life cycle management of products to improve off-patent drug products and developing generic versions of controlled release drug products with high barriers to entry. Elite has five commercial products currently being sold, an additional product approved and soon to be launched, and one additional product under review pending approval by the FDA. Elite's lead pipeline products include abuse resistant opioids utilizing the Company's patented proprietary technology, and a once-daily opioid. They are sustained release oral formulations of opioids for the treatment of chronic pain, which address two of the limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential abuse. Elite also provides contract manufacturing for Actavis and Ascend Laboratories (previously a subsidiary of ThePharmaNetwork and now a subsidiary of Alkem Laboratories Ltd.) and has partnered with Mikah Pharma to develop a new product, with Hi-Tech Pharmacal to develop an intermediate for a generic product, and a Hong Kong based company to develop a branded product for the United States market and its territories. Elite operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ.
Elite Laboratories Files Citizen Petition With the FDA on Brompheniramine Maleate and Pseudoephedrine HCL Extended Release
Elite Laboratories, a wholly owned subsidiary of Elite Pharmaceuticals, Inc. (collectively ""Elite" or the "Company") (OTCBB:ELTP) today announced that the Company submitted a Citizen Petition to the U.S. Food and Drug Administration (the "FDA") requesting that the FDA make a determination that (a) it is suitable to use the currently approved and marketed ANDA product (ANDA 078648, generic to Drixoral brand) as the Reference Listed Drug ("RLD") since the current RLD Drixoral brand is no longer available in the marketplace, and (b) that this currently approved and marketed ANDA product is suitable to use as a RLD for an equivalent active ingredient comprised of a difference salt.
The filing of the Citizen Petition represents another step forward in Elite's continuing efforts to reintroduce its extended release brompheniramine maleate and pseudoephedrine hydrochloride to the marketplace.
Cord Blood America Announces 2013 First Quarter Financial Results
LAS VEGAS, May 15, 2013 /PRNewswire/ -- Cord Blood America, Inc. (www.cordblood-america.com) (OTC Bulletin Board: CBAI) ("CBAI" or the "Company") today announced financial results for the quarter ended March 31, 2013.
First Quarter 2013 Highlights From Continuing Operations
Recurring revenues increased approximately 7% for the three months ended March 31, 2013 to $740,124.
Cash provided by operations totaled $128,970 in the first quarter. This represents 68% of the total full year cash generated in 2012 of $190,323.
EBITDA for the quarter increased 587% to $99,985 from $14,542 in the year ago period.
SG&A decreased 11% to $1.11 million from $1.24 million in the year ago period.
Our cash balance increased 40% to $369,186 compared to the same period a year ago.
article on Naked Short Selling
http://seekingalpha.com/instablog/2406831-shortracker/651241-naked-short-selling-is-killing-otc-companies
article on Naked Short Selling
http://seekingalpha.com/instablog/2406831-shortracker/651241-naked-short-selling-is-killing-otc-companies
Lewsogge I agree with you 100 percent on your previous post: Fox News Video on MPDD:
article on Naked Short Selling
http://seekingalpha.com/instablog/2406831-shortracker/651241-naked-short-selling-is-killing-otc-companies
BCCI Golden Cross Today - I expect a very strong move North on technicals.
article on Naked Short Selling
http://seekingalpha.com/instablog/2406831-shortracker/651241-naked-short-selling-is-killing-otc-companies
Naked Short Selling Is Killing OTC Companies 1 comment
May 23, 2012 11:15 AM
Shorts are alive and well and, the OTC Markets haven't seen the kind of rampant short pressure that is more and more commonplace today. Small development stage companies, and even profitable companies are being negatively attacked and sucked into a trap of naked short selling, which ultimately sends their stock prices plummeting, and often to the point of no return.
According to OTCShortReport.com a leading data provider of Naked Short Position information, a higher than normal number of companies are contacting them with questions ranging from who is shorting my stock to why are their securities being shorted so heavily. As a data provider, OTCShortReport.com doesn't know who's behind the shorting, but suspicions are it's Market Makers who are operating on a completely different playing field, are taking advantage of the rules.
Market Makers, unlike Brokers, can simply create shares out of thin-air that quite frankly cease to exist under the guise of creating liquidity and keeping markets rolling. The problem is when a Market Maker decides to send your stock in a downward direction, that's it, your company is going down. It doesn't matter whether you try to short squeeze the heck out of them or not, in the end, they always win.
Recently, ISM International (PINKSHEETS ISML), a victim of short selling, was so fed up with the abusive practices taking place with their stock, they contacted OTCShortReport.com regarding the possibility of creating a documentary to expose what is really happening. Only yesterday 73% of ISML was shorted for no apparent reason. Orders come into the stock, and Market Makers simply short against them, and then show up on the bid at much lower prices-waiting like predators. "I spend a great deal of the day explaining to my shareholders that we are being attacked. I have complained to the appropriate authorities, but no one seems to care," says Mario Quenneville, CEO of ISM International.
Naked Short Selling is also a common practice on penny stock promotions. Look at companies like SNPK, POTG, and current promotion GWBU. The short positions in these stocks are huge. Market Makers are building massive short positions in the dollar range, and effectively staying naked-short until these promotions get crushed, and give them the opportunity to cover in the sub-penny range. Of course, these Market Makers face no borrowing fees or lending contracts like regular Brokers, so essentially it's just the wild, wild-west where they know full well they can do whatever they please.
OTCShortReport.com executives say it's not uncommon to see 50% of a stock promotion being shorted. The big traders have lots of money… a lot more than the retail audience, and there is no urgency to cover these positions. Market Makers can't be scared into covering because quite honestly they don't care. A stock can run up 500% and they have proven they will just short more.
We invite investors to take a look at what is happening with this illicit naked short selling practice at www.otcshortreport.com
Feel free to query any OTC Stock you wish, and you'll be surprised at the amount of information you will find.
Naked Short Selling Is Killing OTC Companies 1 comment
May 23, 2012 11:15 AM
Shorts are alive and well and, the OTC Markets haven't seen the kind of rampant short pressure that is more and more commonplace today. Small development stage companies, and even profitable companies are being negatively attacked and sucked into a trap of naked short selling, which ultimately sends their stock prices plummeting, and often to the point of no return.
According to OTCShortReport.com a leading data provider of Naked Short Position information, a higher than normal number of companies are contacting them with questions ranging from who is shorting my stock to why are their securities being shorted so heavily. As a data provider, OTCShortReport.com doesn't know who's behind the shorting, but suspicions are it's Market Makers who are operating on a completely different playing field, are taking advantage of the rules.
Market Makers, unlike Brokers, can simply create shares out of thin-air that quite frankly cease to exist under the guise of creating liquidity and keeping markets rolling. The problem is when a Market Maker decides to send your stock in a downward direction, that's it, your company is going down. It doesn't matter whether you try to short squeeze the heck out of them or not, in the end, they always win.
Recently, ISM International (PINKSHEETS ISML), a victim of short selling, was so fed up with the abusive practices taking place with their stock, they contacted OTCShortReport.com regarding the possibility of creating a documentary to expose what is really happening. Only yesterday 73% of ISML was shorted for no apparent reason. Orders come into the stock, and Market Makers simply short against them, and then show up on the bid at much lower prices-waiting like predators. "I spend a great deal of the day explaining to my shareholders that we are being attacked. I have complained to the appropriate authorities, but no one seems to care," says Mario Quenneville, CEO of ISM International.
Naked Short Selling is also a common practice on penny stock promotions. Look at companies like SNPK, POTG, and current promotion GWBU. The short positions in these stocks are huge. Market Makers are building massive short positions in the dollar range, and effectively staying naked-short until these promotions get crushed, and give them the opportunity to cover in the sub-penny range. Of course, these Market Makers face no borrowing fees or lending contracts like regular Brokers, so essentially it's just the wild, wild-west where they know full well they can do whatever they please.
OTCShortReport.com executives say it's not uncommon to see 50% of a stock promotion being shorted. The big traders have lots of money… a lot more than the retail audience, and there is no urgency to cover these positions. Market Makers can't be scared into covering because quite honestly they don't care. A stock can run up 500% and they have proven they will just short more.
We invite investors to take a look at what is happening with this illicit naked short selling practice at www.otcshortreport.com
Feel free to query any OTC Stock you wish, and you'll be surprised at the amount of information you will find.
Naked Short Selling Is Killing OTC Companies 1 comment
May 23, 2012 11:15 AM
Shorts are alive and well and, the OTC Markets haven't seen the kind of rampant short pressure that is more and more commonplace today. Small development stage companies, and even profitable companies are being negatively attacked and sucked into a trap of naked short selling, which ultimately sends their stock prices plummeting, and often to the point of no return.
According to OTCShortReport.com a leading data provider of Naked Short Position information, a higher than normal number of companies are contacting them with questions ranging from who is shorting my stock to why are their securities being shorted so heavily. As a data provider, OTCShortReport.com doesn't know who's behind the shorting, but suspicions are it's Market Makers who are operating on a completely different playing field, are taking advantage of the rules.
Market Makers, unlike Brokers, can simply create shares out of thin-air that quite frankly cease to exist under the guise of creating liquidity and keeping markets rolling. The problem is when a Market Maker decides to send your stock in a downward direction, that's it, your company is going down. It doesn't matter whether you try to short squeeze the heck out of them or not, in the end, they always win.
Recently, ISM International (PINKSHEETS ISML), a victim of short selling, was so fed up with the abusive practices taking place with their stock, they contacted OTCShortReport.com regarding the possibility of creating a documentary to expose what is really happening. Only yesterday 73% of ISML was shorted for no apparent reason. Orders come into the stock, and Market Makers simply short against them, and then show up on the bid at much lower prices-waiting like predators. "I spend a great deal of the day explaining to my shareholders that we are being attacked. I have complained to the appropriate authorities, but no one seems to care," says Mario Quenneville, CEO of ISM International.
Naked Short Selling is also a common practice on penny stock promotions. Look at companies like SNPK, POTG, and current promotion GWBU. The short positions in these stocks are huge. Market Makers are building massive short positions in the dollar range, and effectively staying naked-short until these promotions get crushed, and give them the opportunity to cover in the sub-penny range. Of course, these Market Makers face no borrowing fees or lending contracts like regular Brokers, so essentially it's just the wild, wild-west where they know full well they can do whatever they please.
OTCShortReport.com executives say it's not uncommon to see 50% of a stock promotion being shorted. The big traders have lots of money… a lot more than the retail audience, and there is no urgency to cover these positions. Market Makers can't be scared into covering because quite honestly they don't care. A stock can run up 500% and they have proven they will just short more.
We invite investors to take a look at what is happening with this illicit naked short selling practice at www.otcshortreport.com
Feel free to query any OTC Stock you wish, and you'll be surprised at the amount of information you will find.
article on Naked Short Selling
http://seekingalpha.com/instablog/2406831-shortracker/651241-naked-short-selling-is-killing-otc-companies
Naked Short Selling Is Killing OTC Companies 1 comment
May 23, 2012 11:15 AM
Shorts are alive and well and, the OTC Markets haven't seen the kind of rampant short pressure that is more and more commonplace today. Small development stage companies, and even profitable companies are being negatively attacked and sucked into a trap of naked short selling, which ultimately sends their stock prices plummeting, and often to the point of no return.
According to OTCShortReport.com a leading data provider of Naked Short Position information, a higher than normal number of companies are contacting them with questions ranging from who is shorting my stock to why are their securities being shorted so heavily. As a data provider, OTCShortReport.com doesn't know who's behind the shorting, but suspicions are it's Market Makers who are operating on a completely different playing field, are taking advantage of the rules.
Market Makers, unlike Brokers, can simply create shares out of thin-air that quite frankly cease to exist under the guise of creating liquidity and keeping markets rolling. The problem is when a Market Maker decides to send your stock in a downward direction, that's it, your company is going down. It doesn't matter whether you try to short squeeze the heck out of them or not, in the end, they always win.
Recently, ISM International (PINKSHEETS ISML), a victim of short selling, was so fed up with the abusive practices taking place with their stock, they contacted OTCShortReport.com regarding the possibility of creating a documentary to expose what is really happening. Only yesterday 73% of ISML was shorted for no apparent reason. Orders come into the stock, and Market Makers simply short against them, and then show up on the bid at much lower prices-waiting like predators. "I spend a great deal of the day explaining to my shareholders that we are being attacked. I have complained to the appropriate authorities, but no one seems to care," says Mario Quenneville, CEO of ISM International.
Naked Short Selling is also a common practice on penny stock promotions. Look at companies like SNPK, POTG, and current promotion GWBU. The short positions in these stocks are huge. Market Makers are building massive short positions in the dollar range, and effectively staying naked-short until these promotions get crushed, and give them the opportunity to cover in the sub-penny range. Of course, these Market Makers face no borrowing fees or lending contracts like regular Brokers, so essentially it's just the wild, wild-west where they know full well they can do whatever they please.
OTCShortReport.com executives say it's not uncommon to see 50% of a stock promotion being shorted. The big traders have lots of money… a lot more than the retail audience, and there is no urgency to cover these positions. Market Makers can't be scared into covering because quite honestly they don't care. A stock can run up 500% and they have proven they will just short more.
We invite investors to take a look at what is happening with this illicit naked short selling practice at www.otcshortreport.com
Feel free to query any OTC Stock you wish, and you'll be surprised at the amount of information you will find.
I bought 200,000 at .011. I am long. I've done research on this company. I know BCCI is a legitimate company, with legitimate products.